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1. ABBREVIATIONS 
 
 
LEDGF            Lens epithelium derived growth factor 
 
            HIV-1              Human immunovirus-1 
 
            CCD             Catalytic core domain 
 
            IBD  Integrase binding domain 
 
           AIDS     Acquired Immune Deficiency Syndrome 
 
           CD4  Cluster domain  
          
           SiRNA  small interfering RNA 
 
           IniI   Integrase interactor 1 
 
           BAF  barrier-to-auto integration-factor 
 
           HMGA1 High Mobility Group chromosomal protein A1 
 
           PC4  positive transcription co-factor 4 
 
           NLS  Nuclear localization sequence  
 
           NTD  N-terminal domain   
 
           CTD  C-terminal domain  
 
           SSC  Strand synaptic complex 
 
           BME                 Beta mercaptoethanol 
           HECT  Homologous to E6AP C- terminus 
           IPTG                Isopropyl β-D-1-thiogalactopyranoside  
           ISG15              Interferon Stimulated Gene 
           MMS2              Methyl Methane Sulfonate 
           PCR                 Polymerase Chain Reaction 
           PMSF              Phenylmethylsulfonyl fluoride 
           PRR                 Post Replication Repair 
           RING               Really Interesting New Gene 
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           SUMO               Small Ubiquitin Related Modifier. 
           SWI/SNF           Switch/Sucrose NonFermentable 
           TRAF6               Tumor Necrosis Receptor Associated Factor 
           UEV1A              Ubiquitin Enzyme Variant 1 
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2. ABSTRACT 
 
Part I 
 
 
Ubc13, an ubiquitin-conjugating enzyme (Ubc), requires the presence of an Ubc 
variant (Uev) for polyubiquitination. MMS2 (methyl methane sulfonate) and 
Uev1A has similar sequence homology. The difference in these two variants is 12 
Amino acid residues. But these 12 amino acids residues are dictating two different 
pathways in which one pathway leads to innate immunity (Uev1a with UBC13) 
and other leads to DNA Repair pathway (MMS2 with UBC13).Generating 
mutations in MMS2 and analyzing the MMS2 mutants with UBC13, followed by 
ubiquitin assays will help us to understand which amino acid residue is important 
for the pathway specificity. 
 
Part II 
 
LEDGF/p75 is an important transcriptional cofactor which binds specifically to 
HIV-1 integrase. Two regions of the IN CCD dimer were identified to be involved 
in the interaction with LEDGF/p75, one among them which centers around on 
residues Trp131 and Trp132 while the second extends from Ile161 up to Glu170. 
The side chain of LEDGF residue Ile-365 projects into a hydrophobic pocket 
formed by IN B-chain residues Leu-102, Ala-128, Ala- 129, and Trp-132 and A-
chain residues Thr-174 and Met-178. The side chain of HIV-1 IN Trp-131 is 
involved in hydrophobic contacts with Phe-406 and Val-408 in LEDGF in the form 
of strong π-π interactions. Trp-131 was the only CCD residue that underwent 
significant rearrangement upon formation of the IN-LEDGF/p75 complex. And it 
is also having interactions which consist of a hydrogen bridge between Trp131 and 
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the backbone Carbonyl of Arg405 in the IBD protein. So mutations in T131 
residue by removing its Indole ring might create some conformational changes and 
helps in reducing the interactions with LEDGF/p75. 
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3. INTRODUCTION 
Part I 
              Ubiquitin, a 76 Amino acid residue protein is primarily attached to Lysine 
residues in target   proteins through an enzymatic cascade reactions  catalyzed by 
E1, E2, and E3 enzymes. 
Post-translational modification of proteins is one of major mechanisms employed 
by eukaryotic cells to expand the functional diversity of the proteome. The 
covalent modification of proteins with Ubiquitin is highly conserved in eukaryotes. 
The human genome encodes over 300 enzymes dedicated to Ubiquitin conjugation 
and approximately 100 Ubiquitin proteases, termed as Deubiquitinating enzymes, 
which remove Ubiquitin from modified proteins (Nijman et al., 2005; Bengtson et 
al., 2008). Ubiquitin conjugation is necessary for fundamental cellular processes, 
including cell cycle progression, transcriptional regulation, DNA repair, apoptosis, 
and protein trafficking, endocytosis and signal transduction. Thus represents an 
important form of post-translational modification in the cell (Pick art 2001; 
Felberbaum et al., 2006; Karin et al., 2008) 
3.1 Ubiquitin Family 
Ubiquitin is the member of small protein modifiers. There are two possibilities for 
ubiquitin to bind proteins. One way of binding is with C-terminal of Gly76 is 
attached to the € amino group of a lysine by isopeptide linkage with target proteins. 
The other way of ubiquitin binding is binding to Ubiquitin itself. Because it 
contains seven lysine residues, which function as acceptor sites for building 
polyubiquitination chains. Proteins can therefore be modified at a single lysine 
with one Ubiquitin molecule (monoubiquitination), at several lysine residues with 
Ubiquitin monomers (multi-monoubiquitination), or through chains of lysine-
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linked polyUbiquitin (polyubiquitination). The modification of proteins with a 
single Ubiquitin molecule, can serve as a signal for endocytosis (Hicke 2001)  
3.2 Ubiquitin-like modifiers 
A family of proteins termed Ubiquitin-like modifiers shares structural similarity 
with Ubiquitin. Total nine Ubiquitins including ISG15 and SUMO; have 
demonstrated capability of covalently modifying protein targets (Hochstrasser 
2009). Conjugation of most Ubiquitin-like modifiers follows a similar mechanistic 
framework to Ubiquitin and requires catalysis by dedicated E1, E2, and E3 
enzymes. 
3.3 Ubiquitin ligases (E3) 
E3 Ubiquitin ligases catalyze the final step of Ubiquitin transfer to substrate. With 
over 300 members encoded in the human genome, E3 ligases comprise the largest 
class of Ubiquitin conjugation enzymes (Bengtson et al., 2008). They are divided 
into three classes based on their mechanism of function (1) RING and RING-like 
(2) HECT (3) neither RING nor HECT  
3.3.1 RING E3 ligases  
RING domains contain a cross-brace structure of eight conserved cysteine or 
histidine residues coordinating two zinc ions (Wing et al., 1999; Jensen et al., 
1999) Variations in the number of zinc ions distinguish related domains. The U-
box domain lacks zinc ions. Charged and polar residues, instead of the cysteine and 
histidine residues, forming salt bridges and hydrogen bonds that stabilize a similar 
cross-brace structure. The RING-H2 domain contains three zinc-binding sites. The 
RING domain of the E3 ligase recruits E2~Ubiquitin thioester complex. The region 
of interaction between RING E3s and E2 enzymes were elucidated through 
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structural studies of RING-E2 complexes (Dye & Schulman 2007; Deshaies & 
Joazeiro 2009)  
The role of RING E3 during catalysis is to bring the E2~Ubiquitin thioester in 
proximity of a lysine residue for modification. Evidence indicates that merely 
binding of E2 and RING E3s is not sufficient for catalysis (Deshaies and Joazeiro 
2009) and it is possible that the RING domain induces a conformational change in 
E2~Ubiquitin to promote Ubiquitin discharge. A conserved Asn residue located 
near the E2 enzyme active site aids in RING-dependent or E3-independent transfer 
of Ubiquitin to a substrate lysine. This Asn residue functions to stabilize the 
oxyanion intermediate that forms during nucleophilic attack of the substrate lysine 
residue on the E2~Ubiquitin thioester (Hanlon et al., 2003).  RING E3s may 
function to allosterically activate the E2 by promoting a conformation change that 
positions the Asn residue in the oxyanion hole to stabilize the charged intermediate 
(Hanlon et al., 2003; Yu et al., 2005)  
3.3.2 HECT E3 ligases  
The HECT (homologous to E6AP C-terminus) domain is a 350 residue C-terminal 
domain catalytic defined member of E6AP family (Scheffner et al., 1994) .In 
contrast to the RING domain E3s, the human genome encodes 28 HECT E3s 
(Scheffner et al., 1995).This class of enzymes is differed from RING E3s by its 
catalytic mechanism. HECT E3s form an E3~Ubiquitin intermediate on a 
conserved catalytic cysteine contained within the HECT domain prior to catalyzing 
isopeptide bond formation.  
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The catalytic and substrate-binding functions of HECT E3s are typically separated 
in different domains, with substrate binding mediated by N-terminal protein-
protein interaction modules.  
 
 
 
 
Figure 3.3 
The ubiquitylation pathway: E1 enzyme activates Ubiquitin by adenylating Ub’s C-
terminal in an ATP-Dependent manner and forms E1 Ub~thioester complex. E1 Ub~thioester 
complex was associated with E2 and transfers Ub to the E2 catalytic cystiene The RING E3 
brings  E2 Ub~thioester complex in close proximity to the substrate and HECT E3 forms an 
E3~Ubiquitin intermediate on a catalytic cysteine.(Adapted from  Fang & .Weissman 2004) 
 
3.4 Uev1A  
UEV1a encodes an ubiquitin (Ub) conjugating enzyme (Ubc) variant (Uev). Uev1 
is a member of the protein family that serves as a co-factor for Ubc13-catalyzed 
Lys63-linked poly-Ub chains (McKenna et al., 2001; Moraes et al., 2001; 
Pastushok et al., 2003) 
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Tumor necrosis factor receptor associated factor 6 (TRAF6) is an important 
signaling molecule involved in a diverse array of physiological processes. It has 
been proposed that TRAF6, a RING finger-containing protein, acts as an ubiquitin 
ligase (E3) and a target for Lys-63 linked polyubiquitination mediated by Ubc13–
Uev, an ubiquitin conjugating (E2) complex are required for the interaction. The 
TRAF6 RING finger domain mediates physical interaction with Ubc13 (Xiao et 
al., 2004) 
3.5 MMS2  
MMS2 encodes a 145-amino acid, 15.2-kDa protein with significant sequence 
homology to a conserved family of Ubiquitin-conjugating proteins. MMS2 
interacts with RAD6 to direct the RAD6–RAD18 complex results in PRR and this 
interaction requires the amino terminal of RAD6. It is believed to be targeted to the 
sites of damage by the DNA-binding RING finger protein RAD18 (Von Borstel 
1978). RAD6 system is mediated by another chromatin-associated RING finger 
protein, the SWI/SNF homolog RAD5 (Williamson & Fogel 1985) 
gi|40806164|ref|NP_068823.2|      MPGEVQASYLKSQSKLSDEGRLEPRKFHCKGVKVPRNFRLLEELEEGQKG 50 
gi|2947301|gb|AAC05381.1|          --------------------MAVS-------------------------------TGVKVPRNFRLLEELEEGQKG 25 
 
 
gi|40806164|ref|NP_068823.2|      VGDGTVSWGLEDDEDMTLTRWTGMIIGPPRTIYENRIYSLKIECGPKYPE 100 
gi|2947301|gb|AAC05381.1|          VGDGTVSWGLEDDEDMTLTRWTGMIIGPPRTNYENRIYSLKVECGPKYPE 75 
                                                       
gi|40806164|ref|NP_068823.2|      APPFVRFVTKINMNGVNSSNGVVDPRAISVLAKWQNSYSIKVVLQELRRL 150 
gi|2947301|gb|AAC05381.1|          APPSVRFVTKINMNGINNSSGMVDARSIPVLAKWQNSYSIKVVLQELRRL 125 
                                                       
 
gi|40806164|ref|NP_068823.2|      MMSKENMKLPQPPEGQCYSN 170 
gi|2947301|gb|AAC05381.1|          MMSKENMKLPQPPEGQTYNN 145 
 
Figure 3.5.Sequence alignment of human UEV1a and MMS2 are shown. Important non 
identical residues in both variants are labeled with colors.(MMS2 and Uev1a sequence adapted 
from uniprot and multiple alignment sequence was done by using ClustalW tool) 
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Part II 
 
INTRODUCTION 
1
st
 time AIDS was reported in 1981 and the discovery of its causing Agent is 
human immunodeficiency virus (HIV). In 1983, this virus has killed more than 2.9 
million people. About 4.3 million were infected in 2006. At the end of 2006 
approximately 39.5 million people are living with the disease. The emergence of 
HIV strains resistant to the presently available anti-HIV drugs is an important 
factor in therapy failure. Therefore it is extremely important that to develop new 
compounds which helps to target HIV replication. 
 
HIV was discovered in 1983 as the causative agent of Acquired Immune 
Deficiency Syndrome, AIDS (Gallo et al., 1984; Barré-sinoussi et al., 1983; Levy 
et al., 1984) and is a member of the Lentiviruses, which belongs to a subfamily of 
the retroviruses. Retroviruses are enveloped RNA viruses and are characterized by 
a reverse transcription step in their replication cycle. Unlike other retroviruses, 
which require cell division for productive infection, lentiviruses can stably 
integrate their proviral DNA into the genome of dividing as well as non-dividing 
cells. Based on genome organization and phylogenetic relationship with other lent 
viruses, HIV can be divided into 2 types: HIV-1 and HIV-2. Worldwide infection 
with HIV-1 is more common. 
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Figure 1: Replication cycle of HIV-1 
HIV-1 replication is of two steps. 
1
st
 step nonspecific attachment of the virus to cell surface and enter into the cells (step a) the 
reverse transcription (step b) and the integration of the proviral DNA (step c).  
2
nd
 step includes all events from transcription of the integrated DNA (step e) to budding (step d) 
and maturation and results in the formation of infectious viral particles. (Adapted from Meadows 
et at., 2009) 
 
3.1 Cellular Co-Receptors 
 
One of the first cellular co-factors used in the replication cycle of HIV are the 
cellular receptor CD4 and co-receptors CXCR4 or CCR5. The first efforts at 
targeting cellular co-factors for antiretroviral therapy have focused on these 
receptors. A 32 bp deletion in the gene coding for the CCR5 co-receptor of HIV-1 
results in a receptor that is severely truncated and cannot be detected at the cell 
surface. Individuals, homozygous for this deletion, are resistant to infection with 
an HIV-1 CCR5 strain (Benkirane, et al., 1997) 
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3.2 Cellular co-factors of Integrase 
 
Besides these, cellular co-factors for HIV-1 integration have also been identified. 
Among them  (1) barrier-to-auto integration-factor (BAF) (2) the High Mobility 
Group chromosomal protein A1 (HMGA1) (3) Integrase interactor 1 (IniI) and 
(4)Lens epithelium-derived growth factor (LEDGF/p75). 
 
3.2.1 Lens epithelium-derived growth factor (LEDGF/p75) 
 
LEDGF/p75 was identified as a HIV-1 Integrase-interacting protein by co-
immunoprecipitation of nuclear extracts of cells stably over expressing HIV-1 
integrase from a synthetic gene (Cherepanov, et al., 2003) during the course of 
purifying the general transcriptional co-activator PC4  a ~75 kDa polypeptide was 
co-purified. This polypeptide was identified as p75 or the positive transcription co-
factor 4 (PC4)-interacting protein.  LEDGF/p75, 530 AA long, is a member of the 
hepatoma-derived growth factor (HDGF) family and contains, a conserved N-
terminal PWWP-domain (Amino acid from 1-91) thought to be involved in 
protein-protein interactions (Stec, et al., 2000) and chromatin binding (Gee,  et al., 
2004). Besides the PWWP domain, LEDGF/p75 also contains a nuclear 
localization signal (NLS) (Amino acid from 148-156). A conserved domain of 
LEDGF/p75 that is necessary and sufficient for the binding of LEDGF/p75 to the 
HIV-1 integrase was mapped to just 83 amino acids, spanning the residues (347 – 
429): the integrase binding domain or IBD. This IBD is essential but not sufficient 
to enhance the strand transfer activity of HIV-1 IN (Cherepanov, et al., 2004) 
LEDGF/p75 proved to be essential for nuclear localization and chromosomal 
association of HIV-1 IN since transient and stable RNA-interference (RNAi)-
mediated knockdown of endogenous LEDGF/p75expression abolished 
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nuclear/chromosomal localization of integrase [Maertens, et al., 2003; Llano, et al., 
2004). LEDGF/p75 is probably present in the reintegration complex (Llano, et al., 
2004).  
 
 
Figure 3.2.1: LEDGF/p75 structural organization. 
 
The N-terminal portion of LEDGF/p75 is responsible for binding chromatin. The PWWP domain 
binds to methylated histones as well as DNA nonspecifically. The AT-hooks CR1, CR2 and CR3 
each contribute to nonspecific DNA binding. The C-terminal end harbors an integrase binding 
domain (IBD) which binds IN in a hydrophobic pocket at the CCD-CCD dimer interface 
 
3.2.2 Importance of IBD residues in IN-LEDGF/p75 interaction 
. 
The C-terminal of LEDGF/p75, an 83-amino acid domain interacts with lentiviral 
INs, including HIV-1 IN, and is thus named the integrase binding domain (IBD) 
(Gee, et al., 2004). The LEDGF/IBD is comprised of 5 alpha-helices, of which 4 
(α1, α2, α4 and α5) form a right-handed helical bundle which are connected by α3. 
A cluster of hydrophobic residues at the top of the LEDGF/IBD structure formed 
by the loops between α1-α2 and α4-α5 have been shown to interact with IN. 
Mutagenesis these amino acids, Ile366, Asp366 and Phe406 abrogated 
LEDGF/IBD-IN interactions while Val408 severely reduced binding. This 
confirmed that the V-shaped loop is critical for protein-protein interaction 
(Cherepanov, et al., 2004) Biochemical studies have also demonstrated that the IN 
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CCD in necessary and sufficient to bind LEDGF/p75. Additionally, the crystal 
structure of the LEDGF/IBD in complex with the HIV-1 IN CCD dimer revealed 
that the LEDGF/IBD binds at the CCD-CCD dimer interface. In the crystal 
structure the Ile366 of LEDGF/IBD forms hydrophobic interactions with HIV-1 IN 
residues Leu102, Ala128, Ala129, Try132, Thr174 and Met178. Additionally, 
LEDGF/IBD residues Phe406 and Val408 have hydrophobic interactions with 
HIV-1 IN Try131 and LEDGF/IBD Asp366 forms hydrogen bonds to the 
backbone amides of HIV-1 IN Glu170 and His171. (De rijck, et al., 1997) 
Although the IN CCD is necessary and sufficient to bind LEDGF/IBD, the IN 
NTD contributes to the high-affinity binding of IN to LEDGF/p75 (Cherepanov, et 
al., 2004).  
 
3.3 HIV-1 Integrase protein 
 
Integrase is a 288-amino acid protein (32 kDa) encoded by the end of the pol gene. 
It is produced as part of the Gag-Pol polypeptide precursor, from which it is 
released by viral protease-mediated cleavage (Olivier delelis, et al., 2008) It is 
comprised of three domains: the N-terminal domain (NTD) which contains the Zn-
binding motif (HH-CC type), the catalytic core domain (CCD) which contains the 
DDE catalytic triad that coordinates essential Mg2+ ions, and the C-terminal 
domain (CTD) which contains an SH3-like fold (Andarke et al., 1995). Each of 
these domains contributes to protein multimerization(Wang jy, et al., 2001; Chen 
jc, et al., 2000; Jenkins et al.,1999; Andarke et al., 1995).Integrase is an important 
therapeutic target as its function is essential for viral replication. A tetramer of IN 
assembles on the viral DNA ends to form then stable synaptic complex (SSC) and 
catalyzes two reactions necessary for the integration of linear viral DNA into the 
host chromatin (Brown  et al,.) IN initially removes a GT dinucleotide from the 3′-
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terminus of each viral DNA end (3′-processing), and then integrates recessed viral 
DNA ends into the target DNA in a staggered fashion through concerted 
transesterification reactions (DNA strand transfer). IN is comprised of three 
domains: the N-terminal domain (NTD) which contains the Zn-binding motif (HH-
CC type), the catalytic core domain (CCD) which contains the DDE catalytic triad 
that coordinates essential Mg2+ ions, and the C-terminal domain (CTD) which 
contains an SH3-like fold (Engelman et al., 2011). Each of these domains 
contributes to protein multimerization (Wang jy, et al., 2001; Chen jc, et al., 2000; 
Jenkins et al., 1999; Andarke et al., 1995) 
 
 
Figure 3.3: IN structural organization 
 
IN is comprised of 3 domains, an N-terminal domain (NTD), a catalytic core domain C-terminal 
domain (CCD) and a C-terminal domain (CTD). The NTD contains an HHCC motif for the 
coordination of a Zn2+ ion that is important for the multimerization of the full-length protein. 
The CCD contains the DDE active site and contributes to DNA binding. The CTD contributes to 
DNA binding as well as the multimerization of the full-length protein. 
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3.4 INTERACTION OF T131 WITH PHE406, VAL408 AND ARG405 OF 
LEDGF/p75 
 
 Structure obtained from PDB and interactions were analyzed by using PyMol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4A: Trp-131 is involved in hydrophobic contacts with Phe-406 and Val-
408 in the form of strong π-π interactions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure3.4B: Hydrogen bond between Trp131 and the backbone Carbonyl of 
Arg405 
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4. OBJECTIVES  
 
Part I 
1) Mutation of N57I residue of MMS2 by overlap PCR 
2) To clone the mutant gene and purify the mutant protein. 
 
Part II 
1) Mutation of T131F residue of IN by using Pymol 
2) Dock both wt LEDGF IBD and mutant HIV-1 IN CCD by using Cluspro tool  
3) Analyzing the interactions with LEDGF/p75 by using Discovery studio 4.0    
    Software 
 
 
5. RATIONALE 
 
Part I 
 
MMS2 and Uev1A have similar sequence homology. The only change is 12 amino 
acid residues in both the proteins. But these 12 amino acids change, dictating two 
different pathways in which one pathway leads to innate immunity ( Uev1a with 
UBC13)and other goes to DNA Repair pathway(MMS2 with UBC13). By creating 
mutations in one of the E2 variants (MMS2) will help us to understand which 
amino acid residue is important for specificity of signaling pathway when it 
interacts with UBC13. 
Part II 
 
The side chain of HIV-1 IN Trp-131 is involved in hydrophobic contacts with Phe-
406 and Val-408 in LEDGF in the form of strong π-π interactions. And it is also 
having interactions which consist of a hydrogen bridge between Trp131 and the 
backbone Carbonyl of Arg405 in the IBD protein. So mutations in T131 residue by 
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removing its indole ring might create some conformational changes and helps in 
reducing the interactions with LEDGF/p75. 
 
6. METHODS  
 
 
Part I 
 
6.1 Cloning of wild type MMS2 and Mutant MMS2 
The plasmids carrying ORF coding for Uev1a, MMS2 and UBC13 proteins in the 
study have been purchased from Origene technologies U.S.A. The MMS2 gene 
was PCR amplified and cloned into pRSETA vector having in frame HIS–tag at 
the N-terminus with a protease cleavage site. Followed by  screening, PCR 
amplification of desired insert with wild type and mutant primers of both forward 
and backward(Wild type MMS2 NR-7  5` CGT GGA TCC ATG GCG GTC TCC 
ACA GGA G 3`  NR-8  5` CCG CTC GAG TTA ATT GTT GTA TGT TTG TCC 
TTC TG 3`  N57I mutant MMS2 primers NR-22 
GGGCCACCTAGGACAATTTATGAAAACAG 3`NR-23 5` CTG TTT TCA 
TAA ATT GTC CTA GGT GGC CC 3` which creates AvrII site ) and Insert 
release  strategy by using Restriction Enzymes(Bam-XhoI) was performed. 
 
6.2 Recombinant protein expression and purification 
6.2.1 Protein expression 
The positive clone was transformed into BL21 (DE3) pLys cells in LB Agar 
media, with ampicillin (50µg/ul) and chloramphenicol (30µg/µl) and incubated at 
37⁰C at 250rpm for 13-14hrs.Picked 3 colonies from BL21 (DE3) pLysS 
transformed plate and inoculated into 3ml culture media by adding 50µg/ul of 
25 
 
ampicillin, incubated at 37⁰C at 250rpm for overnight which serve as a pre-
inoculum. Took 5% preinoculum into fresh 3ml culture tubes with 50µg/ul of 
ampicillin and grow the bacterial culture till it reaches 0.5-0.6 OD at 600nm.Induce 
with 1mM IPTG and incubated at 37⁰C at 250rpm for 4hrs. Loaded the samples in 
12% SDS PolyAcrylamideGel with reference to protein ladder   
6.2.2 Protein purification 
Added 1% of pre-inoculum into 125ml LB media by adding 50µg/ul of ampicillin 
and grown the bacterial culture till OD reaches 0.5-0.6. Induced with 1mM IPTG 
and incubated at 37⁰C at 250rpm. Mutant Protein purification was performed by 
using Ni NTA column, in which cells were lysed in lysis buffer(50mMTris-Cl 
(pH8), 150mM NaCl, 20mM imidazole,1mM BME, 0.5% Triton-X100,1mM 
PMSF) followed by sonication and centrifuged at 14.8k rpm for 10 min. Added 
cell lysate to Ni NTA column and collected Flow through followed by adding wash 
buffer (50mMTris-cl (pH8), 150mM NaCl, 20mM imidazole) and collected wash 
which then followed by elution buffer and collected eluted fractions(50mMTris-cl 
(pH8), 150mM NaCl, 400mM imidazole) loaded on in 12% SDS Poly Acryl amide 
Gel with reference to protein ladder.  
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Part II 
 
6.1 Computational methods 
 
Solution structure of IBD of LEDGF (1ZE9) and HIV Integrase protein (4DMN) 
was obtained from PDB. Structure was visualized and analyzed using PyMol. 
Initially mutation of T131F was done in Pymol by removing non bonded 
molecules and ligands. 
Steps to mutate one amino acid on a protein structure 
Open from the menu Wizard > Mutagenesis next Click on the residue for choosing 
the mutant followed by selecting a conformational state in the new mutagenesis 
panel menu .Click on the No Mutation button and select a new amino acid (e.g. 
PHE). Click Apply and click done when finished with the Mutagenesis Wizard. 
 
6.1.1 Cleaning the crystal structure of protein before docking 
 
Open the crystal structure of IBD of LEDGF (1ZE9) and T131F mutant of HIV 
Integrase protein (4DMN) in Discovery Studio and change the display style. 
Change the protein representation to flat ribbon and colour by Secondary type. 
Click on Structure in the toolbar and Crystal Cell in the dropdown and click on 
Remove Cell. Click on Macromolecules Tab, Protein Report and if any ligands or 
water molecules found, delete them. In the same tab, click on Prepare Protein 
followed by Clean Protein and Show Clean Report. Alternate confirmations of 
proteins will be reported. 
 
This is followed by Prepare Protein Step. In the window that appears, change the 
pH and Ionic strength according to conditions and Click on Run. On job 
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completion, a file opens as protein name prep and reports about missing residues 
etc. Validate the structure on clicking X-ray (or Macromolecules) Tab and click on 
Validate Protein Structure followed by Perform Validations, Check Structure. 
 
6.1.2 Docking with Cluspro2.0 
 
Docking was performed by using Cluspro 2.0 version 
(http://cluspro.bu.edu/home.php). It is an online server which represents a web-
based program for the computational docking of protein structures. Upload the 
coordinate files of two protein structures through ClusPro web interface, or enters 
the PDB codes. Both Wt and mutant protein structure were uploaded separately 
and ran the job. 
Cluster is the group of docked models in which high no of models will be more 
favorable and stable. These models were opened in Discovery studio 4.0 and 
analyzed interactions. 
6.1.3 Analyzing the interactions by using Discovery studio 
 
Open the cluspro model in Discovery studio 4.0 and select all interactions and 
distances from Ligand interaction tab and analyze the interactions with desired 
residues. 
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7. RESULTS AND DISCUSSIONS: 
 
Part I 
7.1 Screening of wild type MMS2: 
Digested PCR product amplified product of wild type MMS2 and digested 
pRSETA vector (Bam-XhoI) was incubated at 37⁰C for 4hrs followed by Ligation 
with T4 DNA ligase and Transformed 100ul on DH5α plate. Picked colonies from 
DH5α plate and incubated at 37⁰C for 13hrs followed by screening the colonies 
and DNA was run on 0.6% agarose for 90min at 50v. Lane 1 & 3 showed slower 
mobility shift when compared with pRSETA vector of on 2.9kb. 
 
                                                
 
Figure 7.1: Sreening of wild type MMS2.Lane1 & 3 shows wild type MMS2 screened 
colonies with pRSETA vector backbone and MMS2 insert showing slower mobility; Lane2: 
shows only pRSETA vector. 
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7.2 Bam-XhoI Restriction Digestion for MMS2 insert release 
The restriction enzymes for screening wild type MMS2 was used for screening 
strategy of insert release. Prepared master-mix (autoclaved water,10x BSA,Buffer-
3,BamHI and XhoI) to that added screened wild type MMS2 and incubated at 37⁰C 
for 8hrs.Uncut DNA and Digested DNA with reference to  1kb DNA Ladder was 
run on 0.6% agarose at 50v for 90min. Insert release was observed at 435 bp in 
Lane2 of Wild type MMS2 which was digested with Bam-XhoI. 
 
                                 
Figure7.2: Bam-XhoI Restriction Digestion for insert release:Lane1: shows wild 
type MMS2 Uncut DNA; Lane2: shows wild type MMS2 Digested DNA with Bam-XhoI; 
Lane3: shows 1kb DNA Ladder; Insert release was observed at 435 bp in Lane2 of Wild type 
MMS2 
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7.3 Screening of mutant MMS2 (N57I)  
Digested MMS2 mutant (N57I) PCR amplified product of and digested pRSETA 
vector (Bam-XhoI) was incubated at 37⁰C for 4hrs followed by Ligation with T4 
DNA ligase and Transformed 100ul on DH5α plate. Picked 9 colonies from DH5α 
plate and incubated at 37⁰C for 13hrs followed by screening the colonies and DNA 
was run on 0.6% agarose for 90min at 50v. Lane4 showed slower mobility shift 
when compared with pRSETA vector of on 2.9kb 
 
 
 
 
 
 
 
 
 
                               
 
 
 
 
Figure 7.3: Screening of mutant MMS2 (N57I).Lane1-5 & 7-10 shows mutant MMS2 
screened colonies; Lane4: shows mutant MMS2 insert (N57I) along with vector backbone 
showing slower mobility shift; Lane6: shows pRSETA vector (2.9kb); 
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7.4. Bam-XhoI Restriction Digestion for mutant MMS2 (N57I) insert release 
The restriction enzymes for screening wild type MMS2 was used for screening 
strategy of insert release. Prepared master-mix (autoclaved water,10x BSA,Buffer-
3,BamHI and XhoI) to that added screened MMS2 mutant N57I and incubated at 
37⁰C for 3hrs.Uncut DNA and Digested DNA with reference to  1kb DNA Ladder 
was run on 0.6% agarose at 50v for 90min. Insert release was observed at 435bp in 
Lane2 of mutant MMS2(N57I) which was digested with Bam-XhoI 
 
                                              
Figure 7.4: Bam-XhoI Restriction Digestion for mutant MMS2 (N57I) insert 
release 
Lane1: shows mutant MMS2 (N57I) Uncut DNA; Lane2: shows mutant MMS2 (N57I) Digested 
DNA with Bam-XhoI; Lane3: shows 1kb DNA Ladder. Insert release was observed at 435bp in 
Lane2 of mutant MMS2 (N57I) 
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7.5 Mutant MMS2 N57I screening with AvrII digestion with respect to wild     
type MMS2 
Mutant MMS2 N57I creates AvrII restriction site. Wild type MMS2 doesn’t have 
AvrII restriction site. So to confirm mutant MMS2 N57I insert AvrII Digestion 
was done. Prepared master-mix (autoclaved water, 10x BSA, Buffer-4 and AvrII 
enzyme) to that added screened colonies of both wild type and mutant MMS2. 
Uncut and digested wild type MMS2 and Uncut and digested mutant MMS2 N57I 
along with 1kb DNA ladder was run on 0.6% agarose at 50v for 90min.Lane2 & 3 
of wild type didn’t showed any linearized band. But Lane 4 of mutant MMS2 
which gained AvrII restriction site showed linearized band. 
 
 
 
 
 
 
  
 
 
 
 
Figure 7.5: AvrII digestion for mutant MMS2 N57I insert release 
Lane:1kb DNA ladder;Lane2 Uncut wild type MMS2; Lane3 Digested wild type 
MMS2;Lane4:Digested Mutant MMS2 N57I; Lane5:Uncut Mutant MMS2 N57I; Lane 4 of 
mutant MMS2 which gained AvrII restriction site showed linearized band. 
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7.6 Mutant MMS2 N57I protein purification 
Positive clone of mutant MMS2 was transformed into BL21 (DE3) pLys Cells 
followed by picking colonies and incubated at 37⁰C in shaker at 250rpm for 13hrs, 
grew the bacterial culture till it reaches to 0.5-0.6 OD at 600nm and induced with 
1mM IPTG. Induced culture was pelleted and added lysis buffer to the pellet 
followed by sonication and centrifugation. Collected flow through from cell lysate 
through NI NTA column and also collected wash. Added elution buffer to the 
column and eluted the protein for 5 fractions. The N57I mutant MMS2 protein was 
run at 10% SDS-PAGE with 80v (till the protein samples goes out from the wells) 
for 30 min and 110v for 76 min. The N57I mutant protein band was observed in 
elution fraction 3 & 4 with (approx) 23kDa. 
Figure 7.6:  Mutant MMS2 N57I protein purification:Lane1: cell pellet  was lysed 
in lysis buffer and followed by sonication and centrifuged at 14.8k rpm for 10 min; Lane2 was 
cell lysate; Lane3: was collected as flow through; Lane4: was collected as was; Lane5: 250kDa 
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Protein Ladder;Lane6-10 Elution fractions. Mutant protein was seen in elution fraction 3 & 4 
with (approx) 23kDa 
Part II 
7.1 PyMol Analysis: 
 
Solution structure obtained from PDB was analyzed using PyMol and Distance from T131 
residue of HIV Integrase and Phe406, Val408 and Arg405 of LEDGF IBD was measured. 
 
Figure 7.1A: Trp-131 (green) is involved in hydrophobic contacts with Phe-406 and Val-
408(light pink) in the form of strong π-π interactions. 
 
Figure7.1B: Hydrogen bond between Trp131 (green) and the backbone Carbonyl of 
Arg405 (pink) 
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After creating mutation from T131 to F131 in pymol the conformation of residue 
were changed. The changed conformation was observed by overlapping two 
structures on top of each other in pymol. 
Figure7.1C: wt T131 (light pink) and mutant T131F (orange) was indicated. 
7.2 Docking results 
Total 9 models were generated with wt IBD and wt CCD which starts from 0-9 
belongs 1 cluster. All 9 models posses interactions with T131 residue but Model 6
th
 
which posses least energy and having strong π-π interactions with wt IBD and wt 
CCD were observed in Discovery studio4.0. 
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Figure7.2A: T131 (green) is interacting with Val408 (sky blue) and Phe406 (deep blue) in the 
form of π-π interactions 
69 models were generated with wt IBD and mutant T131F CCD which starts from 
0-25(max) which were separated in 4 clusters. Generation of mutation in HIV 
Integrase residue of T131 alters the conformation of protein structure and helps in 
reducing the interactions with Phe406, Val408 and Arg405. 
From the result which obtained from cluspro, out of 69 models which are grouped 
into 4 clusters, only 3 models were showing interactions with LEDGF IBD.Those 
3 interactions were also with other residues of LEDGF IBD not with Phe406, 
Val408 and Arg405.None of the models were showed interactions with Phe406, 
Val408 and Arg405.By mutating T131 residue the change of conformational state 
and helps in reducing the interaction with LEDGF IBD was observed in docked 
models as well as Discovery studio.   
 
Figure7.2B: Phe131 (Yellow) is interacting with Leu368 (Ash) in the form of π-π interactions 
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Figure7.2C: Phe131 (Ash) is interacting with Val411 (Ash) in the form of π-π interactions 
 
 
Figure7.2D: Phe131 (Yellow) is interacting with Val411 (Ash) in the form of π-π interactions 
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7.3 Energy calculations 
Energy calculations were calculated based on given formula. 
 
E=0.40Erep + -0.40Eatt + 600Eelec + 1.00EDARS 
 
Wt LEDGF IBD and Wt HIV Integrase CCD scores 
Cluster Members Representative Weighted Score 
0 288 Center -666.1  
0 288 Lowest Energy -696.3  
1 285 Center -669.1  
1 285 Lowest Energy -715.3  
2 107 Center -682  
2 107 Lowest Energy -708.6  
3 76 Center -582.8  
3 76 Lowest Energy -655.3  
4 68 Center -587.3  
4 68 Lowest Energy -660.2  
5 37 Center -596.6  
5 37 Lowest Energy -624.8  
6 24 Center -645.4  
6 24 Lowest Energy -645.4  
7 21 Center -578.8  
7 21 Lowest Energy -667.9  
8 18 Center -584.4  
8 18 Lowest Energy -625.3  
9 18 Center -619.1  
9 18 Lowest Energy -619.1  
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Wt LEDGF IBD and Mutant HIV Integrase CCD scores 
Cluster Members Representative Weighted Score 
0 207 Center -751.5  
0 207 Lowest Energy -751.5  
1 145 Center -607.8  
1 145 Lowest Energy -646.3  
2 116 Center -658  
2 116 Lowest Energy -658  
3 76 Center -620.1  
3 76 Lowest Energy -677.4  
4 72 Center -587  
4 72 Lowest Energy -664.9  
5 62 Center -636.1  
5 62 Lowest Energy -657  
6 61 Center -639.8  
6 61 Lowest Energy -664.4  
7 49 Center -622.8  
7 49 Lowest Energy -673.8  
8 34 Center -654.6  
8 34 Lowest Energy -654.6  
9 27 Center -632.2  
9 27 Lowest Energy -640  
10 25 Center -648.7  
10 25 Lowest Energy -648.7  
11 20 Center -596.1  
11 20 Lowest Energy -626.7  
12 19 Center -651.9  
12 19 Lowest Energy -651.9  
13 18 Center -664.2  
13 18 Lowest Energy -664.2  
14 14 Center -619.8  
14 14 Lowest Energy -642.5  
15 12 Center -606.1  
15 12 Lowest Energy -635.8  
16 10 Center -588.1  
16 10 Lowest Energy -617.7  
17 6 Center -650.6  
17 6 Lowest Energy -650.6  
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